Current treatment options for neuroblastoma fail to eradicate the disease in the majority of high-risk patients, clearly mandating development of innovative therapeutic strategies.
Introduction
Successful treatment of high-risk neuroblastoma remains a major challenge in pediatric oncology. This neural crest-derived malignancy accounts for approximately 15% of all childhood cancer mortality in the US (Maris et al., 2007) . Clinical and biological characteristics, such as age at diagnosis, disease stage, histopathology, tumor cell DNA content (ploidy), and copy number status of the N-myc oncogene, allow for stratification of neuroblastoma patients into different risk groups (Brodeur, 2003; Maris et al., 2007) .
About half of all cases are currently classified as high-risk disease, with a mortality rate exceeding 60%, pointing at a compelling need to develop alternative treatment strategies (Maris et al., 2007 ).
An intriguing therapeutic opportunity for a number of human diseases may be offered by a group of ribonucleases endowed with cytotoxic, immunosuppressive, antitumor, angiogenic, and aspermatogenic activities. These enzymes are referred to as Ribonucleases with Special Biological Actions or RISBASEs (D'Alessio, 1993) , as their functions extend beyond the processing and turnover of cellular RNA and the breakdown of dietary RNA. Such specialized ribonucleases are present from prokaryotes to higher mammals and operate in a variety of biological processes, including interstrain competition in bacteria, prevention of self-pollination in plants, pathogen survival within host tissues, antiparasitic, antifungal and antiviral defense, neovascularization, and antitumor action (D'Alessio, 1993; Youle et al., 1993) . Interestingly, two of the beststudied antitumor ribonucleases, onconase and bovine seminal ribonuclease, have shown F o r P e e r R e v i e w 5 profound activity against neuroblastoma both in vitro and in vivo, even in a context of resistance to conventional chemotherapeutic agents (Cinatl et al., 1999 (Cinatl et al., , 2000 Kotchetkov et al., 2000; Michaelis et al., 2007) . The molecular basis underlying the cytotoxicity of these ribonucleases is not fully understood, but it is accepted that this activity requires interaction with the cell membrane, internalization by endocytosis, translocation to the cytosol, resistance to the endogenous ribonuclease inhibitor (RI) in the cytosol as well as to extracellular and intracellular proteases, and cleavage of cellular RNA (Benito et al., 2005; Arnold and Ulbrich-Hofmann, 2006) . Onconase is the only ribonuclease hitherto evaluated in clinical trials, with promising results (Beck et al., 2008) , although some caution is warranted in view of a relatively high renal uptake compared to other ribonucleases (Vasandani et al., 1996) and evidence of acute multifocal proximal renal tubular necrosis in mice treated with onconase (Vasandani et al., 1999) .
We previously identified an evolutionary conserved 3′,5′-exoribonuclease, human polynucleotide phosphorylase (hPNPase old-35 ), in an overlapping-pathway screen (OPS) aimed at delineation of genes displaying coordinated changes in expression during terminal differentiation of human melanoma cells and cellular senescence of progeroid fibroblasts (Leszczyniecka et al., 2002 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 were created by cloning the transgene into a shuttle vector followed by homologous recombination in E. coli of the shuttle vector with an adenoviral vector in which the E1 and E3 regions have been deleted, as described previously (Leszczyniecka et al., 2002; 21 22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  P  e  e  r  R  e  v  i  e  w   9 a minimal volume of serum-free RPMI 1640 medium for 3 h at 37 °C, with rocking of the plates every 15 min, followed by replenishment of complete medium and incubation at 37 °C for the indicated times. The empty adenoviral vector, Ad.vec, was used as a control.
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Flow cytometric analysis of GFP expression
Cells were seeded in 6-well plates (2. 
Detection of coxsackie-adenovirus receptors (CAR) on the cell surface
Quantification of surface expression of CAR was performed as described previously (Lebedeva et al., 2002 Cell cycle and hypodiploidy analysis 
Real-time quantitative reverse transcription-polymerase chain reaction (RT-PCR)
Total RNA was extracted from cells using the RNeasy Mini Kit (Qiagen, Valencia, CA),
with RNase-free DNase I treatment on column. After an additional RQ1 DNase treatment in solution (Promega), first-strand cDNA was synthesized from 2 µg total RNA using the iScript cDNA synthesis kit (Bio-Rad). Relative mRNA expression levels were determined using an optimized two-step SYBR Green I real-time quantitative RT-PCR assay with minor modifications (Vandesompele et al., 2002a) . Primer sequences are available in the public RTPrimerDB database (http://medgen.ugent.be/rtprimerdb/) (Pattyn et al., 2003 (Pattyn et al., , 2006 : and CHAT [3502] . The PCR was run on a
LightCycler 480 instrument (Roche) in duplicate reactions of 7.5 µL, containing 250 nM of each primer and cDNA equivalent to 20 ng of total RNA. Gene expression levels and PCR efficiency, along with its standard error, were calculated using qBasePlus 1.0 analysis software (http://www.biogazelle.com) (Hellemans et al., 2007) , which employs a delta-Ct relative quantification model with PCR efficiency correction and multiple infection of NGP and SK-N-SH cells was confirmed by analysis of caspase-3 and caspase-7 activity (Fig. 5) . Adenovirus-mediated hPNPase old-35 expression evoked a 2-to 3-fold and a 3-to 5-fold increase in caspase-3 and caspase-7 activity in NGP and SK-N-SH cells, respectively, measured 2-3 days after infection at 100 pfu/cell. relates to the possibility of degradation of microRNAs (miRNAs), as has been postulated previously for other cytotoxic ribonucleases (Ardelt et al., 2003) , since cumulating evidence indicates that miRNAs are deeply implicated in tumor biology but of considerably less importance in fully-developed normal cells.
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A more thorough understanding of the molecular mode of action of hPNPase old-35 might also shed light on the relatively resistant phenotype of SHEP cells. It is worth noting that these cells also have a poor response to irradiation (Jasty et al., 1998; Tweddle et al., 2001 ) and to various cytotoxic agents (unpublished observations), pointing at a more general insensitivity of SHEP cells to certain cell death-inducing triggers. This might for instance be related to a yet undefined block on apoptotic effector pathways in SHEP cells (Jasty et al., 1998) , but an alternative hypothesis involves the poor tumorigenicity of these cells. SHEP cells, although widely used in neuroblastoma research, do neither form colonies in soft agar nor tumors when injected in nude mice (Ross and Spengler, 2007) , and hence it can be questioned whether these tumor-derived cells still represent true 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Cells were incubated with mouse monoclonal anti-CAR antibody, washed, stained with FITC-labeled anti-mouse immunoglobulins, washed, analyzed by flow cytometry, and compared with a number of appropriate controls, as described in Material and Methods. The D value, calculated by the Kolmogorov-Smirnov two-sample test for analysis of flow cytometric histograms and reflecting the greatest difference between the cumulative distribution functions derived from the histograms (Young, 1977) , indicated for all cell types in this study the presence of CAR surface expression at the 99.9% confidence level. The peak shift, computed as a ratio (PCAR -Pctrl)/Pctrl with PCAR and Pctrl being the median of the fluorescent peak of the flow cytometric histogram of the CAR-stained cells and of the control cells with the highest FITC signal intensity, respectively, allows for comparison of surface CAR number and availability between different cell types. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 
